Sanofi and Regeneron line up for second place in EU cardio race

Damian Garde Sanofi and Regeneron may be on pace to win the first U.S. approval for a new type of cholesterol treatment, but the pair trails rival Amgen in Europe in a race to make ...

UPDATED: Sanofi and Regeneron pick up a blockbuster cardio approval–with a catch

Damian Garde Sanofi and Regeneron won an expected FDA approval for the first of a new class of cholesterol drugs expected to alter the landscape in cardiology, but regulators stopped ...

Merck cancer drugs and Sanofi, Amgen cardio meds have formularies on high alert

Eric Palmer U.S. drug payers have been able to beat back high prices for some COPD and diabetes drugs, much to the chagrin of GlaxoSmithKline and Sanofi. But several new categories ...

Sanofi buys into NeuroVive’s cardio drug in Korea

Damian Garde Sanofi is betting on the promise of NeuroVive Pharmaceutical's top prospect, buying the South Korean rights to the biotech's Phase III cardiovascular drug. FierceBiotech ...

Novartis looks to squelch neuro worries over its would-be cardio blockbuster

Damian Garde Novartis, at work on a cardio drug widely expected to bring in billions of dollars once approved, is working to tamp down concerns that the oral treatment could increase ...

Investigators link Novartis’ would-be cardio blockbuster to Alzheimer’s risk

John Carroll Novartis' heart failure med LCZ696 has singlehandedly saved the pharma giant's cardio drug development strategy from the embarrassing setback triggered by serelaxin's ...

The Medicines Co.’s FDA-rejected cardio drug finds EU success

Damian Garde European regulators are recommending approval for The Medicines Company's cangrelor, setting up an overseas nod for a blood-thinning drug rejected by the FDA last year. FierceBiotech ...

Sanofi and Regneron prep their cardio contender for FDA review after a Phase III sweep

Damian Garde Sanofi and Regeneron are heading to the FDA with a potential blockbuster cardiovascular treatment, touting positive results from a slew Phase III trials in which the drug ...

Regado slips again as FDA weighs in on halted cardio trial

Damian Garde The FDA has stamped a full clinical hold on a trial Regado Biosciences had voluntarily paused, shouldering its way into any discussion of resuming the study and sending ...

Merck wins FDA approval for a once-vaunted cardio drug

Damian Garde Merck picked up FDA approval for the clot-busting cardio drug vorapaxar, a treatment once billed as a potential warfarin successor before running into some alarming safety ...

EU takes up testosterone drug review on cardio worries

Carly Helfand The FDA has been reviewing testosterone drugs since January of this year on concerns over their cardiovascular safety. Now, its across-the-pond counterpart is following ...

Critics knock JAMA study linking testosterone drugs to cardio risks

Carly Helfand A study the FDA has cited as a reason to investigate the cardiovascular safety of testosterone drugs has come under heavy fire from critics. Physicians and researchers ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS